Active substance-contained gel composite based on multilayer liquid crystal framework and method for producing same

Abstract

The invention discloses an active substance-contained gel composite based on a multilayer liquid crystal framework and a method for producing the same, wherein the gel composite comprises the following components in percentage by weight: 0.1-35% of liquid crystal gel surfactant, 0.2-30% of permeable skin penetration enhancer, 0.5-30% of liquid paraffin, 0.1-20% of gel host material, 3-90% of water, 0.1-15% of active substance and 3-90% of ethanol solution. The active substance-contained gel composite based on the multilayer liquid crystal framework not only has better efficiency, but also can reduce the medicine taking frequency, so the compliance of a user is increased; and meanwhile, a permeable skin way avoids the first-pass effect after the medicine is orally taken and then passes by gastrointestinal tract and liver, so higher bioavailability is obtained.

Description

technical field [0001] The invention relates to a gel composition based on a multilayer liquid crystal skeleton containing active substances and a preparation method. Background technique [0002] Alzheimer's disease, also known as Alzheimer's disease (AD), is a primary degenerative encephalopathy that occurs in old age and early old age, and its characteristic pathological changes are cerebral cortex atrophy, accompanied by β-Amyloid deposition, neurofibrillary tangles, loss of number of large memory neurons, and formation of senile plaques. The daily life ability of AD patients is reduced, which brings endless pain and troubles to themselves and the people around them. The average survival period of AD patients is 5.5 years. After cardiovascular disease, cerebrovascular disease and cancer, AD has become the "fourth killer" of the health of the elderly. In the near future, our country will enter an aging society, accompanied by a problem that cannot be ignored - the incid...

AI Technical Summary

Problems solved by technology

However, the above patents all need to be taken daily and for a long time, which cannot solve the shortcomings of poor compliance and high clinical drop-out rate of AD patients

Chinese patent CN101167697A discloses a long-acting sustained and controlled release composition of donepezil compound and its preparation method, but all of them are injection or oral preparations, which also have the above-mentioned defects

[0006] Chinese patent CN101460156B authorizes a patch-like transdermal therapeutic system containing donepezil with an adhesive as the matrix, but the closed patch is used for long-term medication, the patch area is large, and the skin tolerance is poor. Easy to precipitate in pressure sensitive adhesive

[0007] And the semi-solid composition that adopts traditional percutaneous administration, as emulsified paste, wherein surfactant content is relatively low, and skeleton is made up of amphiphilic molecules, as the preparation of " pharmaceutics " " emulsification and microemulsion technology " report Method and technical principle, it is easy to deform the system by shearing, at this time, the preparation exhibits elastic thixotropic fluid behavior by shearing, and is easily affected by temperature, ions, etc. to cause demulsification and poor stability

[0008] In addition, the arrangement of traditional creams or ordinary hydrogels will create a porous structure in the skin barrier, so it will damage the skin's sebum barrier, speed up the transepidermal water loss, and make the skin vulnerable to external attacks

Images